Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-02-02
1993-10-12
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
424449, 514946, 514947, A61K 31445, A61K 970
Patent
active
052525880
ABSTRACT:
A pharmacological composition for percutaneous administration to a human patient comprises a pharmacologically effective amount of eperisone, a salt thereof, tolperisone or a salt thereof, a water-swellable crosslinked polyvinylpyrrolidone and a base carrier, and exhibits improved percutaneous absorption.
REFERENCES:
patent: 3995047 (1976-11-01), Morita et al.
patent: 4695465 (1987-09-01), Kigasawa et al.
patent: 4830851 (1989-05-01), Tracy et al.
patent: 4837026 (1989-06-01), Rajakhyaksha
patent: 4879275 (1989-11-01), Minaskanian et al.
patent: 5032402 (1991-07-01), Digenis et al.
patent: 5059427 (1991-10-01), Yoshida et al.
patent: 5073375 (1991-12-01), Yoshida et al.
CA:105(10):85214g-Fukuda.
CA:108(19):167333w-Tsuji.
Merck Index; Eleventh Edition, pp. 7700-7701 #7700 (1989).
Patent Abstracts of Japan, vol. 9, No. 66 (C-271) [1789], Mar. 26, 1985, Japan 59-199628.
Azuma Masato
Fujimori Hiroyuki
Negama Tsutomu
Yoshida Mitsuhiro
Criares T. J.
Eisai Co. Ltd.
Sansho Co., Ltd.
Sekisui Kagaku Kogyo Kabushiki Kaisha
Waddell Frederick E.
LandOfFree
Percutaneously absorbable crosslinked polyvinylpyrrolidone eperi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Percutaneously absorbable crosslinked polyvinylpyrrolidone eperi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Percutaneously absorbable crosslinked polyvinylpyrrolidone eperi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1904770